Core Viewpoint - The company has corrected accounting errors in its Q1 2025 financial report, specifically affecting revenue and cost figures, but these corrections do not impact overall profit or the balance sheet [1][2][4]. Accounting Error Correction - The company held a board meeting on August 22, 2025, to approve the correction of accounting errors in the Q1 2025 financial report, following relevant accounting standards and disclosure rules [1][4]. - The correction involved changing the recognition of certain trade transactions from "gross method" to "net method" based on the principle of prudence [1][2]. Financial Impact - The correction affects the following financial metrics for Q1 2025: - Total operating revenue was adjusted from 103,683,885.34 CNY to 45,795,675.76 CNY, a decrease of 57,888,209.58 CNY [2][3]. - Total operating costs were adjusted from 164,016,116.81 CNY to reflect the same decrease in revenue [2][3]. - The adjusted operating revenue shows a year-on-year decrease of 22.50%, attributed to a decline in the pharmaceutical segment's income [3]. Independent and Audit Committee Opinions - The independent directors and audit committee have reviewed the corrections and agree that they comply with relevant regulations, enhancing the accuracy and quality of the financial information [4][5]. Future Measures - The company emphasizes its commitment to improving the quality of information disclosure and plans to enhance training for financial personnel to prevent similar issues in the future [4].

Core Viewpoint - China National Pharmaceutical Group announced the convening of its 30th board meeting on August 8, 2025, to review various proposals, including amendments to existing documents [2] Revenue Composition - For the year 2024, the revenue composition of China National Pharmaceutical Group is as follows: - Pharmaceutical commerce accounts for 77.31% - Pharmaceutical trade accounts for 14.35% - Chemical preparations account for 4.47% - Raw materials account for 2.78% - Traditional Chinese medicine accounts for 1.47% [2]

Group 1 - The core point of the article is that Jimin Health has announced a share buyback program, repurchasing approximately 2.01 million shares, which accounts for 0.3819% of the total share capital, with a total expenditure of about 12.09 million yuan [2] Group 2 - As of July 31, 2025, the company has conducted the share buyback through centralized bidding, with the highest purchase price being 6.13 yuan per share and the lowest at 5.87 yuan per share [2] - For the fiscal year 2024, the revenue composition of Jimin Health is as follows: pharmaceutical manufacturing accounts for 55.95%, medical services for 41.43%, pharmaceutical trading for 1.75%, and other businesses for 0.87% [2]

Core Viewpoint - Liangshan Jiannada Pharmaceutical Trading Co., Ltd., a subsidiary of Good Doctor Group, has been recognized as an employment internship base in Xichang City, providing more practical opportunities for young talents and injecting new momentum into the company's high-quality development [1][3]. Group 1: Company Overview - Liangshan Jiannada is primarily engaged in the wholesale of pharmaceuticals and medical devices, having maintained steady growth for over a decade [3]. - The company has the largest smart traditional Chinese medicine decoction center and modern cold chain logistics center in the Panxi region, responsible for emergency medical supplies in Liangshan Prefecture and Xichang City [3]. - In 2025, the company plans to launch a fully digital management smart traditional Chinese medicine decoction center with a daily decoction capacity of 2,000 prescriptions, showcasing its advanced technical strength and management level [3]. Group 2: Employment Internship Base - As an employment internship base, Liangshan Jiannada will offer multidimensional practical positions covering pharmaceutical circulation, quality management, and warehouse management, allowing interns to engage with digital processes and cutting-edge industry technologies [3]. - The general manager, Zhang Haiyan, emphasized that the internship base serves as a "incubator" for youth growth and a "report card" for the company's social responsibility [3]. - The recognition as an internship base not only provides skill enhancement opportunities for youth but also lays a solid foundation for the company's talent development, reflecting its commitment to stabilizing employment and promoting development [3].